Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 16, 2007 - Issue 9
Submit an article Journal homepage
150
Views
5
CrossRef citations to date
0
Altmetric
Perspective

Discontinued drugs in 2006: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs

Cevdet Ozdemir Marmara University, Division of Pediatric Allergy and Immunology, Istanbul, Turkey
, MD &
Cezmi A Akdis Swiss Institute of Allergy and Asthma Research (SIAF) Obere Strasse 22 CH-7270, Davos, Switzerland +41 81 4100848; +41 81 4100840; [email protected]
, MD
Pages 1327-1344 | Published online: 22 Aug 2007

Bibliography

  • AKDIS M, AKDIS CA: Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. (2007) 119(4):780-791.
  • SHERIDAN C: TeGenero fiasco prompts regulatory rethink. Nat. Biotechnol. (2006) 24(5):475-476.
  • RENZETTI LM, TANNU S, CONNAUGHTON S et al.: Attenuation of airway inflammation and hyperresponsiveness in murine and primate models of asthma by RO0270608, a dual α4β1–α4β7 integrin antagonist. Am. J. Resp. Crit. Care. Med. (2003) 167(7):A640.
  • HIJAZI Y, WELKER H, DORR AE et al.: Pharmacokinetics, safety, and tolerability of R411, a dual α4β1–α4β7 integrin antagonist after oral administration at single and multiple once daily ascending doses in healthy volunteers. J. Clin. Pharmacol. (2004) 44:1368-1378.
  • HIJAZI Y, WELKER H, DORR AE, FRANK K, RENZETTI LM, PATEL I: Evaluation of the effect of multiple-dose administration of R411, a dual α4β1–α4β7 integrin antagonist on the major CYP isoform activities in healthy volunteers. Eur. J. Clin. Pharmacol. (2006) 62:83-85.
  • SINGH J, ADAMS S, CARTER MB et al.: Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma. Curr. Top. Med. Chem. (2004) 4(14):1497-1507.
  • ROLIN S, MASEREEL B, DOGNÉ JM: Prostanoids as pharmacological targets in COPD and asthma. Eur. J. Pharmacol. (2006) 533(1-3):89-100.
  • KESECIOGLU J, HAITSMA JJ: Surfactant therapy in adults with acute lung injury/acute respiratory distress syndrome. Curr. Opin. Crit. Care (2006) 12(1):55-60.
  • LEUNG DY, SAMPSON HA, YUNGINGER JW et al.: Avon Longitudinal Study of Parents and Children Study Team Effect of anti-IgE therapy in patients with peanut allergy. N. Engl. J. Med. (2003) 348(11):986-993.
  • MATTHEWS JB, RAMOS E, BLUESTONE JA: Clinical trials of transplant tolerance: slow but steady progress. Am. J. Transplant. (2003) 3:794-803.
  • BOON L, LAMAN JD, ORTIZ-BUIJSSE A et al.: Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology (2002) 174:53-65.
  • TRAVIS S, YAP LM, HAWKEY C et al.: RDP Investigators Study Group. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm. Bowel Dis. (2005) 11(8):713-719.
  • TREMAINE WJ, BRZEZINSKI A, KATZ JA et al.: AXYS ULCERATIVE COLITIS STUDY GROUP: Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment. Pharmacol. Ther. (2002) 16:407-413.
  • RICE KD, WANG VR, GANGLOFF AR et al.: Dibasic inhibitors of human mast cell tryptase. Part 2: structure–activity relationships and requirements for potent activity. Bioorg. Med. Chem. Lett. (2000) 16;10(20):2361-2366.
  • HESSE C, LUNTZ SP, SIEDLER H, et al.: Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals. Br. J. Clin. Pharmacol. (2006) 61(4):414-419.
  • VAKIL N: Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. (2004) 15;19(10):1041-1049.
  • ITO K, KINOSHITA K, TOMIZAWA A et al.: The anti-secretory and anti-ulcer properties of R-105266, a novel acid pump antagonist. Gut (2001) 49(Suppl. 3) (Abstract 3061).
  • MIWATASHI S, ARIKAWA Y, KOTANI E et al.: Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J. Med. Chem. (2005) 22;48(19):5966-5979.
  • FALGUEYRET JP, DESMARAIS S, OBALLA R et al.: Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J. Med. Chem. (2005) 48(24):7535-7543.
  • SCHREPFER S, DEUSE T, KOCH-NOLTE F, DETTER C, REICHENSPURNER H: FK778: new cellular and molecular mechanisms of action. Transplant. Proc. (2006) 38(3):757-761.
  • KAPLAN MJ: FK-778 Astellas. Curr. Opin. Investig. Drugs (2005) 6(5):526-536.
  • LINK JO, ZIPFEL S: Advances in cathepsin S inhibitor design. Curr. Opin. Drug. Discov. Dev. (2006) 9(4):471-482.
  • VASILJEVA O, REINHECKEL T, PETERS C, TURK D, TURK V, TURK B: Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. (2007) 13(3):385-401.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.